Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

Proportion of participants with maintained response at any of follow up visits

Maintained response is defined as quiescence achieved at respective prior visit and no flare at current visit.

Time frame: Up to Month 12

Percent change in Presenteeism

Assessing percent change in presenteeism

Time frame: Up to Month 12

Proportion of participants with maintained response separately for each follow-up visit

Maintained response is defined as quiescence achieved at respective prior visit and no flare at current visit.

Time frame: Up to Month 12

Percent Change in Total activity impairment

Assessing Percent Change in Total activity impairment

Time frame: Up to Month 12

Changes in total score of Work Productivity & Activity Impairment (WPAI)-UV score

Assessing changes in total score of WPAI-UV score

Time frame: From Month 1 to Month 12

Change in emergency room admissions

Assessing change in emergency room admissions

Time frame: From 6 months prior to treatment start (Week 0 [baseline]) to 12 months after treatment start (total 18 months)

Proportion of participants with treatment response separately for each follow-up visit

Response is defined as participants with no new active inflammatory lesions and having anterior chamber (AC) cell and vitreous haze (VH) grade of \<=0.5+ in both eyes.

Time frame: Up to Month 12

Change from baseline in Best corrected visual acuity (BCVA)

Assessing change from baseline in Best corrected visual acuity (BCVA)

Time frame: From Month 1 to Month 12

Change in cumulative hospital admissions

Assessing change in cumulative hospital admissions

Time frame: From 6 months prior to treatment start (Week 0 [baseline]) to 12 months after treatment start (total 18 months)

Change from baseline in Central Retinal Thickness (CRT)

Assessing change from baseline in Central Retinal Thickness (CRT)

Time frame: From 6 months prior to treatment start (Week 0 [baseline]) to 12 months after treatment start (total 18 months)

Proportion of participants with flare at any of follow up visit

Flare is defined as new active inflammatory lesions or AC cell grade of \>=2+ or VH grade of \>=2+ at least in one eye.

Time frame: Up to Month 12

Percent change in Absenteeism

Assessing percent change in absenteeism

Time frame: Up to Month 12

Percent Change in Total work productivity impairment

Assessing Percent Change in Total work productivity impairment

Time frame: Up to Month 12

Change in outpatient visits

Assessing change in outpatient visits

Time frame: From 6 months prior to treatment start (Week 0 [baseline]) to 12 months after treatment start (total 18 months)

Change in hospitalization days prior to and during Humira® treatment

Assessing change in hospitalization days prior to and during Humira® treatment

Time frame: From 6 months prior to treatment start (Week 0 [baseline]) to 12 months after treatment start (total 18 months)

Change from baseline in intraocular pressure

Assessing change from baseline in intraocular pressure

Time frame: From Month 1 to Month 12